Balfour Sartor, MD
Balfour Sartor, MD, Midget Distinguished Professor of Medicine, Microbiology and Immunology, is the senior author of a study that shows how a novel consortium of bacteria that live in the digestive tracts of healthy individuals can be used to prevent and treat aggressive colitis in humanized mouse models.
A new study published in Nature Communications demonstrates that a consortium of bacteria designed to complement missing or underrepresented functions in the imbalanced microbiome of inflammatory bowel disease (IBD) patients, prevented and treated chronic immune-mediated colitis in humanized mouse models. The study’s senior author, Balfour Sartor, MD, Midget Distinguished Professor of Medicine, Microbiology and Immunology, Co-Director of the UNC Multidisciplinary IBD Center, said the results are encouraging for future use treating Crohn’s disease and ulcerative colitis patients.
“The idea with this treatment is to restore the normal function of the protective bacteria in the gut, targeting the source of IBD, instead of treating its symptoms with traditional immunosuppressants that can cause side effects like infections or tumors,” Sartor said.
The live bacteria consortia, called GUT-103 and GUT-108, were developed by biotech firm Gusto Global. GUT-103 is comprised of 17 strains of bacteria that work together to protect and feed each other. GUT-108 is a refined version of GUT-103, using 11 human isolates related to the 17 strains. These combinations permit the bacteria to stay in the colon for an extended amount of time, as opposed to other probiotics that are not capable of living in the gut and pass through the system quickly.
GUT-103 and GUT-108 were given orally three times a week to “germ-free” mice (no bacteria present) that had been specially developed and treated with specific human bacteria, creating a humanized mouse model. The therapeutic bacteria consortia worked by addressing upstream targets, rather than targeting a single cytokine to block downstream inflammation responses, and reversed established inflammation.
“It also decreased pathobionts – bacteria that can cause harm – while expanding resident protective bacteria, and produced metabolites promoting mucosal healing and immunoregulatory responses,” Sartor said. “Simply put – the treatment increased the good guys and decreased the bad guys.”
Because of the robust results seen in this study, and the need for more alternative therapies for Crohn’s disease, Sartor would like to see GUT-103 and GUT-108 studied in Phase 1 and 2 clinical trials in the future. He plans to continue his work with Gusto Global to further explore uses of the bacterial consortia.
Original Article: ‘Good’ Bacteria Show Promise for Clinical Treatment of Crohn’s Disease, Ulcerative Colitis
More from: University of North Carolina School of Medicine | University of North Carolina at Chapel Hill
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Crohn’s disease
- Take a step to find a cure to Chron’s disease and ulcerative colitis
Join us at the Promenade at Sunset Walk to raise awareness and funds for those fighting and living with Crohn’s disease and ulcerative colitis (collectively known as inflammatory bowel disease or IBD) ...
- Prison documents altered over Crohn's inmate death
A coroner has raised concerns about prison documents being altered over an inmate with Crohn's disease who suffered malnutrition. Mohammed Azizi, 32, who died at HMP Norwich in May, had refused food ...
- Fecal Transplant Shows Promise for Easing Inflammatory Bowel Disease Symptoms
For the study, scientists reviewed results from 15 clinical trials that tested fecal microbiota transplants (FMT) — when stool with healthy microorganisms is inserted into a sick patient’s digestive ...
- Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in Crohn’s disease
Whether human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) could heal luminal ulcers in Crohn’s disease.
- Single-cell analysis reveals mechanisms of a common complication of Crohn's disease
Mount Sinai researchers have published the first study to use single-cell analysis in identifying several pathophysiological mechanisms of abnormal passageways in the digestive system known as ...
Go deeper with Google Headlines on:
Crohn’s disease
[google_news title=”” keyword=”Crohn’s disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Ulcerative colitis
- ‘It’s hard being a stand-up comedian when you poo 15 times a day’
‘Thank god she did,’ says stand-up and podcaster Liam, talking via Zoom amid his comedy tour Chronic Boom, which retells his harrowing (yet hilariously told) journey with ulcerative colitis, a chronic ...
- Take a step to find a cure to Chron’s disease and ulcerative colitis
Join us at the Promenade at Sunset Walk to raise awareness and funds for those fighting and living with Crohn’s disease and ulcerative colitis (collectively known as inflammatory bowel disease or IBD) ...
- How To Prevent Ulcerative Colitis
You might not be able to prevent ulcerative colitis, but you can lower your risk with strategies like gut health support.
- Fecal Transplant Shows Promise for Easing Inflammatory Bowel Disease Symptoms
For the study, scientists reviewed results from 15 clinical trials that tested fecal microbiota transplants (FMT) — when stool with healthy microorganisms is inserted into a sick patient’s digestive ...
- Microscopic Colitis
Microscopic colitis is inflammation of the colon's lining that causes chronic watery diarrhea. Thankfully, there are effective treatments available.
Go deeper with Google Headlines on:
Ulcerative colitis
[google_news title=”” keyword=”ulcerative colitis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]